Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Diplomat Pharmacy Slipped 10.5% on Monday

By Brian Orelli, PhD - Updated Apr 15, 2019 at 11:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's PBM business isn't paying off yet.

What happened

Shares of Diplomat Pharmacy (DPLO) closed down 10.5% on Monday after the company said during a presentation at the J.P. Morgan Healthcare Conference that 2018 revenue would fall at the low end of its previous guidance, and 2019's guidance failed to impress investors.

So what

Previous guidance had revenue falling in the range of $5.5 billion to $5.7 billion, but a quick tally of the 2018 totals shows that the revenue won't top $5.6 billion. On the plus side, at least the final revenue number won't be lower than previous guidance.

On the bottom line, there was a bit of good news with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) expected to come in at $167 million to $170 million, at the high end of the previously communicated range of $164 million to $170 million.

Hands taking medications from a pharmacy shelf

Image source: Getty Images.

The bigger disappointment came from guidance for this year, with revenue expected to hover in the $5.6 billion to $5.8 billion range, just a 3% increase at the midpoints of both year's guidance ranges. Guidance for adjusted EBITDA in 2019 was also disappointing, with flat to low-single-digit percentage increases year over year.

Diplomat Pharmacy's move into the pharmacy benefits manager space hasn't gone particularly smoothly. The company combined multiple acquisitions into CastiaRx, which was able to garner $35 million in revenue from new business this year. But that gain was overwhelmed by the loss of $200 million in previously disclosed Medicare Part D contracts, and the loss of an additional $120 million from new client losses and the pricing impact of contract renewals.

Now what

Diplomat Pharmacy is looking to turn CastiaRx around in 2019, hinting that it plans to make "key senior management changes." The company has also employed the counsel of an external consultant to help improve CastiaRx's performance, as it goes for new contracts in 2019 and tries to mitigate additional losses of current customers. Investors should get to hear more about the plan when the company releases complete fourth-quarter results in late February.

Check out the latest Diplomat Pharmacy earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Diplomat Pharmacy, Inc. Stock Quote
Diplomat Pharmacy, Inc.
DPLO

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.